On August 27, 2018 Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (View Source) reported to announce that Richard Purcell, the Company’s Executive Vice President of Research & Development will participate in a panel discussion at the Cambridge Healthtech Institute’s Immuno-Oncology Summit at the Seaport World Trade Center in Boston, MA (https://www.immuno-oncologysummit.com/) on August 30, 2018. The panel discussion will focus on current trends and future prospects for immunotherapy in the treatment of cancer. Additionally, Mr. Purcell will provide an overview of the relaunched clinical development program of the HER2/neu immunotherapeutic vaccine, AE37, together with strategies to advance the proprietary Ii-Key technology under development at the Company’s wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The introduction of checkpoint inhibitors has been revolutionary in the practice of clinical oncology, but is only effective in roughly 30% of patients across a variety of cancers," said Mr. Purcell. "The complementary mechanism of action of AE37 (T-cell activation), and encouraging results obtained in triple negative breast cancer patients, strongly suggest that the combined use of AE37 with pembolizumab (Keytruda) will provide significantly greater efficacy than either alone."
The Immuno-Oncology Investing & Partnering Forum is taking place on Thursday, August 30th and the session Novel Therapeutics in Cancer Immunotherapy will take place at 1:30 pm EDT and consist of company presentations followed by Q&A with the audience. The conference is taking place at the Seaport World Trade Center in Boston, MA, and the session room is Beacon Hill 1